NTC
MYGN icon

North Tide Capital’s Myriad Genetics MYGN Stock Holding History

North Tide Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,150,000
Closed -$19.2M – 17
2016
Q4 		$19.2M Buy
1,150,000
+150,000
+15% +$2.71M 3.28% 11
2016
Q3 		$20.6M Buy
+1,000,000
New +$25.4M 2.24% 14
2015
Q1 		– Sell
-1,100,000
Closed -$37.5M – 24
2014
Q4 		$37.5M Buy
1,100,000
+100,000
+10% +$3.55M 2.52% 16
2014
Q3 		$38.6M Hold
1,000,000
– – 2.94% 15
2014
Q2 		$38.9M Hold
1,000,000
– – 2.72% 16
2014
Q1 		$34.2M Buy
1,000,000
+500,000
+100% +$15.5M 2.88% 12
2013
Q4 		$10.5M Buy
+500,000
New +$12.6M 0.92% 23

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

North Tide Capital's MYGN Position: Q1 2017 in Review

North Tide Capital sold out of Myriad Genetics (MYGN) in Q1 2017, closing a stake of 1,150,000 shares — an estimated $19.2M sold.

North Tide Capital first reported a position in MYGN in Q4 2013 and held it in 7 quarters. The position peaked at $38.9M in Q2 2014. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2017.

  • North Tide Capital reported no remaining Myriad Genetics position as of Q1 2017 after selling out during the quarter.
  • North Tide Capital sold 1,150,000 Myriad Genetics shares in Q1 2017, an estimated $19.2M.
  • North Tide Capital first reported a position in Myriad Genetics in Q4 2013 and held it in 7 quarters.
  • North Tide Capital's Myriad Genetics position peaked at $38.9M in Q2 2014.
  • 233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2017.

Based on North Tide Capital's 13F filing for Q1 2017, filed 15 May 2017.